Hopes of adagrasib getting approval have increased after Amgen’s (NASDAQ:AMGN) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC. Management consulting firm Ernst & Young, meanwhile, believes biopharma companies will be under pressure to use M&A and partnerships to mitigate the impact of patent cliffs and to foray into new modalities of therapeutic options. 5 Great REITs to Buy as Inflation Surges Additionally, it has a robust gene therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications.